It is suitable for use in adults, adolescents and children aged 4 years and older with a body weight above 15kg. The recommended dose is 150mg in patients over 40kg and 2mg/kg for those between 15 and 40kg.
Ilaris is administered as a single dose via subcutaneous injection once every eight weeks. Treatment should be initiated and supervised by a specialist experienced in the diagnosis and management of CAPS.
Further information: Novartis Pharmaceuticals